申请人:ENANTA PHARMACEUTICALS, INC
公开号:US20200095258A1
公开(公告)日:2020-03-26
The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, thereof:
which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
本发明公开了以下式(I)的化合物或其药学上可接受的盐:其抑制由乙型肝炎病毒(HBV)编码的蛋白质或干扰乙型肝炎病毒的生命周期功能,并且还可用作抗病毒剂。本发明还涉及包含上述化合物的药物组合物,用于治疗患有HBV感染的受试者。该发明还涉及通过给予包含本发明化合物的药物组合物来治疗受试者的HBV感染的方法。